An inspiring week in Thailand with the PDP Funders Group. From ravidasvir for #HepatitisC to the #DengueAlliance, we witnessed how local expertise and global partnerships can turn innovation into access. #GlobalHealth #HepC
October 10, 2025 at 8:08 AM
An inspiring week in Thailand with the PDP Funders Group. From ravidasvir for #HepatitisC to the #DengueAlliance, we witnessed how local expertise and global partnerships can turn innovation into access. #GlobalHealth #HepC
A major step toward #HepatitisC elimination in Thailand: Together with GPO & Pharco, we signed an MoU to register ravidasvir—an affordable treatment developed through South-South collaboration. An effort to expand access and save lives of those living with #HepC in Thailand. dndi.org/press-releas...
July 1, 2025 at 8:47 AM
A major step toward #HepatitisC elimination in Thailand: Together with GPO & Pharco, we signed an MoU to register ravidasvir—an affordable treatment developed through South-South collaboration. An effort to expand access and save lives of those living with #HepC in Thailand. dndi.org/press-releas...
New data presented by Datuk Dr Radzi Abu Hassan at the 2025 #EASLCongress showed that the ravidasvir/sofosbuvir treatment can be safely shortened from 12 to 8 weeks. This shorter regimen is intended for people living with #HepC who do not have cirrhosis.
Link to the poster: dndi.org/wp-content/u...
Link to the poster: dndi.org/wp-content/u...
June 30, 2025 at 11:20 AM
New data presented by Datuk Dr Radzi Abu Hassan at the 2025 #EASLCongress showed that the ravidasvir/sofosbuvir treatment can be safely shortened from 12 to 8 weeks. This shorter regimen is intended for people living with #HepC who do not have cirrhosis.
Link to the poster: dndi.org/wp-content/u...
Link to the poster: dndi.org/wp-content/u...
The WHO recognizes a Malaysian-developed hepatitis C medication as an essential drug.
The medication, ravidasvir (combined with sofosbuvir), was added to the WHO’s Essential Medicines List (EML) in 2023, marking a milestone for Malaysia in affordable hepatitis C treatment
thesun.my/style-life/g...
The medication, ravidasvir (combined with sofosbuvir), was added to the WHO’s Essential Medicines List (EML) in 2023, marking a milestone for Malaysia in affordable hepatitis C treatment
thesun.my/style-life/g...
WHO recognises a Malaysian-developed hepatitis C medication as necessary drug
PETALING JAYA: The World Health Organization (WHO) has placed a hepatitis C medication partially developed in Malaysia to its list of essential medici...
thesun.my
June 25, 2025 at 6:18 AM
The WHO recognizes a Malaysian-developed hepatitis C medication as an essential drug.
The medication, ravidasvir (combined with sofosbuvir), was added to the WHO’s Essential Medicines List (EML) in 2023, marking a milestone for Malaysia in affordable hepatitis C treatment
thesun.my/style-life/g...
The medication, ravidasvir (combined with sofosbuvir), was added to the WHO’s Essential Medicines List (EML) in 2023, marking a milestone for Malaysia in affordable hepatitis C treatment
thesun.my/style-life/g...
#Ravidasvir was a medical milestone for Malaysia.
It shows what people-centric partnerships and political will can achieve.
As Dato' Dr Radzi said, South-South cooperation is a model for #innovation in the Global South.
At DNDi, the work continues. Affordability and access remain our focus.
It shows what people-centric partnerships and political will can achieve.
As Dato' Dr Radzi said, South-South cooperation is a model for #innovation in the Global South.
At DNDi, the work continues. Affordability and access remain our focus.
Developing Countries Can Lead in Medical Innovation | by Muhammad Radzi Abu Hassan - Project Syndicate
Muhammad Radzi Abu Hassan shows how regional collaboration and targeted investment can improve access to therapeutics and diagnostics.
www.project-syndicate.org
April 24, 2025 at 3:27 AM
#Ravidasvir was a medical milestone for Malaysia.
It shows what people-centric partnerships and political will can achieve.
As Dato' Dr Radzi said, South-South cooperation is a model for #innovation in the Global South.
At DNDi, the work continues. Affordability and access remain our focus.
It shows what people-centric partnerships and political will can achieve.
As Dato' Dr Radzi said, South-South cooperation is a model for #innovation in the Global South.
At DNDi, the work continues. Affordability and access remain our focus.
This! #DNDi’s Hepatitis C work in Malaysia is a great example of what open science can do in real life: affordable, effective treatment, developed through collaboration and tested where it’s most needed. Ravidasvir + sofosbuvir is proof that drug development doesn’t have to follow the status quo.
Did you know that we can manage patents in a way that serves the public good?
Our Intellectual Property & Access Leader shares why, together with our partners from the @asapdiscovery.bsky.social, we are filing a #patent for a promising new #molecule that we developed together.
shorturl.at/IgL80
Our Intellectual Property & Access Leader shares why, together with our partners from the @asapdiscovery.bsky.social, we are filing a #patent for a promising new #molecule that we developed together.
shorturl.at/IgL80
How patents can serve the common good
YouTube video by Drugs for Neglected Diseases initiative (DNDi)
youtube.com
April 11, 2025 at 3:29 AM
This! #DNDi’s Hepatitis C work in Malaysia is a great example of what open science can do in real life: affordable, effective treatment, developed through collaboration and tested where it’s most needed. Ravidasvir + sofosbuvir is proof that drug development doesn’t have to follow the status quo.
📃Scientific paper: Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects
Ref.: American Society for Microbiology, 2021
➡️ Continued on ES/IODE
Ref.: American Society for Microbiology, 2021
➡️ Continued on ES/IODE
February 22, 2025 at 2:00 PM
📃Scientific paper: Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects
Ref.: American Society for Microbiology, 2021
➡️ Continued on ES/IODE
Ref.: American Society for Microbiology, 2021
➡️ Continued on ES/IODE
A recent meeting in Bangkok between @dndi.org, Pharco Corporation Egypt, Government Pharmaceutical Organisation (GPO) & Mahidol University discussed HepC patients’ limited access to Ravidasvir. Thank you GPO & Assoc Prof Surakit for hosting. Ravidasvir will improve the lives of 2M people in Thailand
January 29, 2025 at 4:34 AM
A recent meeting in Bangkok between @dndi.org, Pharco Corporation Egypt, Government Pharmaceutical Organisation (GPO) & Mahidol University discussed HepC patients’ limited access to Ravidasvir. Thank you GPO & Assoc Prof Surakit for hosting. Ravidasvir will improve the lives of 2M people in Thailand
Because of the price gouging by Gilead the Malaysian and Thai governments worked with small drug companies and developed ravidasvir as an alternative, a course of treatment is $300.
dndi.org/viewpoints/2...
dndi.org/viewpoints/2...
The story of a ‘political drug’ against hepatitis C | DNDi
Dr François Bompart, Director of the Hepatitis C Initiative at DNDi from 2018 to 2020, shares the story of the development of a new antiviral drug for hepatitis C in a Q&A.
dndi.org
January 28, 2025 at 7:36 PM
Because of the price gouging by Gilead the Malaysian and Thai governments worked with small drug companies and developed ravidasvir as an alternative, a course of treatment is $300.
dndi.org/viewpoints/2...
dndi.org/viewpoints/2...